The Paradigm Peptides Case: What a 70-Month Sentence Means for "Research Use Only" Peptides (September 2026)
A federal judge gave the owner of Paradigm Peptides 70 months for selling untested, mislabelled products to 54,000 customers: what the court record established, what it never showed about the peptide vials, why the research-use-only label protected nobody, and how to check a certificate of analysis yourself.
On 30 July 2026 a federal judge in South Bend, Indiana, sent the owner of Paradigm Peptides to prison for 70 months. Two days later, searches for the company hit their highest point of the year, and "daniel murphy paradigm peptides case" became the fastest-rising query attached to the word "peptides" in the United States.
Here's the caveat that gets dropped from most of the coverage. The contamination proven in this case was in SARM pills, not in peptide vials. And the things that put two people in prison (forged lab certificates, a fake "made in the USA" claim, a research-use-only label that the owner admitted was fiction) are not exotic. They are the same trust signals you are asked to rely on every time you buy from a vendor you cannot inspect. So what did the court record establish, what is still unknown, and what should it change about how you buy? Let's dive in.
TLDR
What happened? Matthew Kawa, 48, owner of Paradigm Peptides, was sentenced to 70 months in federal prison. His sister and main employee, Jennifer Stechkober, 32, got 16 months. Both pleaded guilty in December 2025.
What did they sell? Peptides, SARMs, and hCG, to more than 54,000 customers in all 50 states and more than 80 countries between 2019 and 2024, for about $5 million.
What was in the products? Many of the SARMs were testosterone, not the compound on the label. Nothing was tested before sale. No public test results exist for the peptide vials.
The harm: Customers reported chronic acne, suppressed natural testosterone, cardiac problems, and psychological effects up to suicidal ideation. One customer, Daniel Murphy, was diagnosed with steroid-induced psychosis.
Legal Status (September 2026): Selling unapproved drugs for human use is a federal crime whatever the label says. The July 2026 FDA committee vote did not change that, and the FDA sent five more warning letters to research-use-only sellers on 24 August 2026.
What Happened, and Why Is It Trending Now?
Let's get this straight. This is not a story about a regulator sending a stern letter. It is a criminal case that ended in prison time, which is rare in this market.
Kawa ran Paradigm Peptides (legally Paradigm R.E. LLC) through paradigmpeptides.com and shipped from Michigan City, Indiana. The conduct in the case runs from April 2019 to March 2024, when the business was shut down (U.S. Attorney's Office, Northern District of Indiana, 2026).
He pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead, and to illegally importing merchandise. Stechkober pleaded guilty to the first charge. Judge Cristal C. Brisco sentenced them on 30 July 2026, and told Kawa he had left "an incredible trail of harm" (CBS News, 2026).
On top of the prison terms, the court entered a $5 million money judgment against Kawa and ordered $78,317.52 in restitution, owed jointly by both defendants.
The search spike has a second cause: timing. The sentencing landed one week after the FDA's advisory committee voted to recommend six peptides for pharmacy compounding, the subject of our July 2026 FDA update. BPC-157, one of those six, was among the unapproved drugs Kawa was charged with selling (CBS News, 2026).
The same month Washington moved toward opening one door for peptides, a federal court slammed another one shut.
What Paradigm Claimed vs What the Record Shows
Before it went offline, Paradigm looked like a lot of vendor sites look today. Here is each claim next to what the defendants admitted or prosecutors established.
What customers were told: Manufactured in the company's own US laboratories. What the record shows: Imported from Asia, including China and India.
What customers were told: Tested to ensure the highest quality, 99% purity. What the record shows: No product was tested before sale.
What customers were told: Backed by laboratory certificates of analysis. What the record shows: Certificates were forged.
What customers were told: Licensed and registered with the FDA. What the record shows: False. The FDA had sent warning letters instead.
What customers were told: SARMs sold as labelled, as dietary supplements. What the record shows: Many were testosterone, a controlled substance.
What customers were told: For research use only. What the record shows: Kawa admitted he knew the products were sold for human consumption.
Read that last row twice. In his plea, Kawa stated: "I knew that Paradigm's products were being marketed and sold for human consumption" (CBS News, 2026). The disclaimer was on every label, and it counted for nothing.
What the Evidence Actually Shows
A lot of claims are circulating about this case. Some come from the court record, some from reporting, and some from vendors using the case to sell their own products. Those are not equal.
Finding: Guilty pleas, 70 and 16 month sentences, $5 million judgment, $78,317.52 restitution. Source: Department of Justice. Status: Established.
Finding: More than 54,000 customers, 50 states, more than 80 countries. Source: Department of Justice. Status: Established (prosecutors' estimate).
Finding: Many SARMs were actually testosterone. Source: Department of Justice. Status: Established.
Finding: All six SARM products the government tested contained testosterone. Source: CBS News, citing prosecutors. Status: Reported from court filings.
Finding: Certificates of analysis were forged. Source: CBS News and BBC, citing the pleas. Status: Reported from court filings.
Finding: FDA seized SARM products for testing by September 2023. Source: BBC. Status: Reported.
Finding: 167 victims came forward for restitution. Source: BBC. Status: Reported.
Finding: FDA warning letters in 2020 and 2022. Source: Department of Justice. Status: Established; only the 2020 letter is in the FDA's public database.
Finding: Paradigm's peptide vials were contaminated or underdosed. Source: None found. Status: Not established.
That last row matters. The peptides were charged as unapproved new drugs, and they were sold with the same forged paperwork and the same absence of testing. But no public document we could find reports what was in the vials.
Untested is not the same as contaminated. It means nobody knows, and that includes the person who sold it.
A note on the warning letters. The public 2020 letter, dated 7 December 2020 and co-signed by the Federal Trade Commission, was about thymosin alpha-1 marketed with COVID-19 claims (FDA, 2020). We could not locate the 2022 letter in the FDA's database, so we are relying on the Department of Justice for its existence.
The Harm Record
The Department of Justice lists what customers reported: skin irritation and chronic acne, drops in natural testosterone that required replacement therapy, cardiac health issues, and stress, anxiety, and psychological problems up to suicidal ideation.
The case has a name attached because of Daniel Murphy, a 32-year-old marketing consultant from Tennessee. He began taking Paradigm's SARMs in January 2023, believing they were a tested dietary supplement (BBC, 2026).
Over the following months he developed insomnia, severe cystic acne, grandiose thinking, and then paranoia. He came to believe his wife was plotting against his business and that his mother-in-law meant to kill him. He had no history of mental illness.
He ran out of product in December 2024 and began to improve. In February 2025 a letter from the Department of Justice told him that Paradigm's SARMs contained testosterone. He had a leftover bottle tested by an independent lab, and it came back positive (CBS News, 2026).
A psychiatrist, Dr Erik Messamore, diagnosed steroid-induced psychosis and gave evidence in the proceedings. Murphy is also suing Paradigm in a civil case, which Kawa is contesting. That suit has not been decided.
Here is the part worth sitting with. By the BBC's account the FDA had seized and tested Paradigm's SARMs by September 2023. Murphy kept taking them for more than a year after that, and nobody told him.
For context, the FDA warns that even genuine SARMs carry risks including heart attack, stroke, liver injury, and psychosis (FDA, 2023). Murphy was exposed to a different drug entirely, at a dose nobody measured.
Why "Research Use Only" Did Not Protect Anyone
The law looks at intended use, not at the label. If the marketing, the dosing guidance, and the customer emails all point at human use, the product is a drug, and an unapproved one.
The FDA made the same point in writing a month after the sentencing. On 24 August 2026 it sent warning letters to five online sellers: NuScience Peptides, Royal Peptides, Peptide Partners, Peak Performance Peptides, and Tex Peptides (McDermott Will and Schulte, 2026).
Every one of them used a research-use disclaimer. The FDA set it aside, pointing to therapeutic marketing language, a peptide dose calculator on the seller's site, and bacteriostatic water sold alongside injectable peptides (FDA, 2026).
State regulators are moving the same way. Ohio's pharmacy board declared research-labelled drugs unlawful for clinics and medical spas in December 2025, and Alabama's medical board barred physicians from dispensing research-grade peptides in June 2026 (McDermott Will and Schulte, 2026).
The disclaimer protects the seller right up until someone checks. It never protected the buyer at all.
What a Certificate of Analysis Can and Cannot Tell You
Paradigm's customers did what careful buyers are told to do. They looked for purity claims and lab certificates. The certificates were fake.
So treat a certificate as a claim to be checked, not as proof. Here is what checking looks like.
Verify it with the lab, not the vendor. A certificate names a laboratory and a report number. Contact the lab or use its lookup page. A PDF on a vendor's site proves nothing on its own.
Match the batch. The lot number on the certificate should match the lot number on your vial. A certificate for a different batch tells you about a different batch.
Look at what was tested. Purity and identity are two tests. Sterility and endotoxin are two more. Most vendor certificates cover only the first two.
Be suspicious of identical numbers. The same 99% figure on every product is a marketing line, not a measurement.
Check what other buyers found. Independent testing paid for by customers is harder to forge than a vendor's own paperwork. Our vendor directory carries community ratings and discussion for that reason.
None of this makes an unapproved product safe. It narrows one risk, which is that the vial is not what the label says. We covered the contaminants that turn up in research-grade peptides in our TB-500 safety piece.
One more thing. Paradigm's site is gone, but CBS News found a similarly named site, on a different domain, selling research peptides with near-identical label design. That company says it has no affiliation with Kawa or the original business. A familiar name is not a track record.
The Legal and Regulatory Situation
April 2019: Start of the conduct covered by the case.
7 December 2020: FDA and FTC warning letter to Paradigm R.E. LLC.
2022: Second FDA warning letter, per the Department of Justice.
September 2023: FDA has seized SARM products for testing, per the BBC.
March 2024: Paradigm Peptides shut down.
February 2025: Department of Justice letters reach customers.
10 December 2025: Both defendants plead guilty.
23 to 24 July 2026: FDA advisory committee recommends six peptides for compounding.
30 July 2026: Sentencing: 70 months and 16